Statins Market Size, Share, and Growth Forecast from 2025 - 2032

The global statins market is predicted to reach a size of US$ 16.6 Bn by 2025. It is anticipated to showcase a CAGR of 3.1% during the forecast period to attain a value of US$ 20.6 Bn by 2032.

As per Persistence Market Research (PMR), rising incidence of cardiovascular diseases like atherosclerosis, coronary artery disease, and stroke are prominent growth drivers. Aging population, especially in developed countries like the U.S., Europe, and Japan, is leading to an increasing number of patients requiring cholesterol-lowering medications like statins.

• The World Health Organization (WHO) reports that more than 17 million people die from cardiovascular diseases each year, and this number is set to surge as populations age.

Statins are considered one of the most effective treatments to reduce cholesterol and prevent such diseases. Global prevalence of hyperlipidemia (high cholesterol) in adults is estimated to be 40% to 50%, further contributing to a high demand for statin drugs.

Key Highlights of the Industry

• Pharmaceutical companies are investing in the development of new and effective statin formulations.
• Fixed-dose formulations are gaining traction as these provide enhanced patient adherence and cost-effective treatments.
• Identification of genetic biomarkers could enhance patient outcomes and decrease side effects.
• Rising health insurance coverage for preventive medication is likely to ensure broader patient access to statins.
• Statins market in North America is set to exhibit a CAGR of 3.8% through 2032 owing to rising focus on preventive health measures.
• By therapeutic treatment, the cardiovascular disorders segment will likely generate a share of 39% in 2025.

Clinical Guidelines Reinforced Statins as First-line Treatment of Dyslipidemia from 2019 to 2024

The statins market growth was average at a CAGR of 2.7% during the historical period from 2019 to 2024. Nearly 18 million deaths annually are attributed to heart-related conditions, driving demand for lipid-lowering drugs like statins. Introduction of generic statins contributed to cost reduction and widespread adoption. For example,

• Research studies linking statin use to reduced COVID-19 mortality rates led to a surging demand, with statin prescriptions increasing by 12% during the pandemic's peak.

Clinical guidelines from the American Heart Association (AHA) and the European Society of Cardiology (ESC) reinforced statins as the first-line treatment for managing dyslipidemia. Research on genetic markers for lipid metabolism also led to tailored statin therapies.

Rise of Remote Monitoring is Likely to Enhance Medication Adherence through 2032

The global market for statins is estimated to exhibit a CAGR of 3.1% through 2032. Potential growth during this period is attributed to increasing awareness of preventive healthcare, thereby boosting adoption of statin in high-risk populations.

Remote monitoring and digital prescriptions are anticipated to enhance medication adherence. Development of novel lipid-lowering therapies, including next-generation statin are likely to contribute to growth.

Genetic testing is likely to assist in determining which patients are more likely to respond to statins, allowing for more precise and effective treatment regimens. Governments in developed countries, such as the U.S., Canada, and EU nations, are likely to extend cholesterol-lowering programs as part of their national health initiatives.

Growth Drivers

Clinical Evidence of Statins Showing Reduction in Heart Attack Risks to Propel Growth

Statins are widely prescribed due to their strong clinical evidence showing a reduction in the risk of heart attack, stroke, and cardiovascular-related death. Clinical guidelines from The American Heart Association (AHA) strongly recommend statins for secondary prevention, helping to lower LDL cholesterol levels and prevent further cardiovascular events. For example,

• A meta-analysis published in The Lancet in 2016 confirmed that statins reduce the risk of major cardiovascular events by 25% for every 1 mmol/L reduction in LDL cholesterol.
• According to The National Institute for Health and Care Excellence (NICE) in the U.K., statins are recommended for individuals with a high risk of developing heart disease, with over 90% of patients being prescribed statins following clinical endorsement.

Concerns Regarding Side Effects and Long-term Medication Requirements to Hamper Demand

Public perception and growing scepticism regarding the long-term use of statins have become significant restraining factors in the statins industry. These factors stem from concerns over side effects, need for long-term medication, and a shift toward natural or alternative treatments. As a result, a few patients are becoming hesitant about starting or continuing statin therapy, especially in cases where they do not have clear, immediate risks of cardiovascular events. For example,

• Research published in the Journal of the American Medical Association (JAMA) found that up to 15% of statin users report muscle-related side effects, contributing to negative public sentiment and concerns about the long-term safety of these drugs.

Development of Combination Therapies to Spur Avenues due to Enhanced Outcomes

Development of combination therapies, where statins are combined with other pharmacological agents, is a significant trend in the statins industry. These combination therapies offer improved therapeutic outcomes, better patient compliance, and enhanced cardiovascular risk management.

Ezetimibe is a cholesterol absorption inhibitor that works by reducing the absorption of cholesterol from the gastrointestinal tract. When combined with statins, it offers enhanced LDL cholesterol-lowering effects, particularly for patients who require further lipid-lowering therapy despite taking statins alone. For instance,

• The IMPROVE-IT trial, one of the largest studies involving patients with acute coronary syndrome, found that combining simvastatin with ezetimibe led to a 6.4% reduction in major cardiovascular events compared to simvastatin alone.

Introduction of PCSK9 inhibitors (like alirocumab and evolocumab) has revolutionized lipid-lowering therapy, offering a more potent way to lower LDL cholesterol levels. For example,

• The ODYSSEY trial demonstrated that combining alirocumab (PCSK9 inhibitor) with statins led to a 15% reduction in major adverse cardiovascular events (MACE) in patients with a history of heart attacks, compared to placebo.

Drug Class Insights

Ability to Effectively Lower Cardiovascular Disease Risks to Bolster Atrovastatins Demand

Atorvastatins is projected to hold a share of 38.4% in 2025. Atorvastatin is more potent than other statins, leading to its widespread use for high cholesterol and cardiovascular disease prevention. For example,

• Studies have shown that atorvastatin reduces LDL cholesterol levels by 60% at the highest dose, which is significantly higher than other statins.

Atorvastatin, marketed under brand names like Lipitor (Pfizer) and various generic versions, has consistently remained among the top prescribed drugs globally. For instance,

• In the U.S., atorvastatin accounted for around 24 million prescriptions in 2022, making it one of the most dispensed statin medications.
• Clinical trials like the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) demonstrated that atorvastatin reduced cardiovascular events by 36% over five years, solidifying its role as a first-line therapy.

Atorvastatin offers dose flexibility for patients with varying levels of cholesterol and cardiovascular risks, increasing its prescription base. After Pfizer's Lipitor patent expired in 2011, the market witnessed a flood of low-cost generic atorvastatin options, making it highly accessible. For example,

• As of 2023, atorvastatin held over 40% of the global statin drug sales due to the availability of cost-effective generics.

End User Insights

Patients to Opt for Care across Hospitals as these Provide Precise and Timely Statin Prescriptions

Hospitals are anticipated to hold a share of 76.8% in 2025. Hospitals often handle acute cases of myocardial infarction, unstable angina, and other critical CVD conditions, where statins are prescribed as part of immediate care protocols. For example,

• Clinical studies indicate that administering high-dose statins prior to Percutaneous Coronary Intervention (PCI) can reduce complications by 34%.

Healthcare guidelines from organizations like the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) recommend statin therapy immediately after acute coronary syndrome (ACS) events. For example,

• Statins are prescribed in over 75% of discharge cases for patients treated for CVD in hospitals.

Hospitals play a key role in prescribing statins for patients undergoing surgeries, particularly vascular and cardiac procedures, to prevent future cardiac events. Hospitals have unique diagnostic tools to assess cholesterol levels and CVD risks, leading to precise and timely statin prescriptions. Regular lipid profile monitoring in hospital outpatient departments further supports sustained statin use.

Rising Prevalence of High Blood Pressure to Create Surging Demand in North America

North America statins market is estimated to hold a share of 41.2% in 2025. Cardiovascular disease remains the leading cause of death in the U.S. It contributes to 659,000 deaths annually, creating sustained demand for cholesterol-lowering drugs like statins. For example,

• According to the CDC (Centers for Disease Control and Prevention), 47% of American adults have high blood pressure or other risk factors for heart disease.
• A study published in the Journal of the American Medical Association (JAMA) found that 50% of U.S. adults aged 40 to 75 were eligible for statin therapy based on cholesterol guidelines.

The statins industry benefits from robust insurance coverage, ensuring patients can afford branded and generic statins. Updated guidelines from the American Heart Association (AHA) emphasizing statin use in preventive care further bolster market growth.

Favorable Norms by European Society of Cardiology in Europe to Bolster Growth

Europe statins market is anticipated to hold a share of 17% in 2025. Cardiovascular diseases (CVDs) are the leading cause of mortality in the region.

• According to The European Heart Network, CVD accounts for 45% of all deaths in Europe, which is equivalent to 4 million deaths annually.

High prevalence of cardiovascular diseases in Europe augments demand for cholesterol-lowering therapies like statins. The region has one of the highest statin consumptions across the globe. For example,

• Countries like the U.K., Germany, and Netherlands have statin utilization rates of 160 defined daily doses (DDDs) per 1,000 inhabitants per day, reflecting widespread adoption for preventive healthcare.

The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) recommend statin therapy as a first-line treatment for hyperlipidemia and cardiovascular risk management. These clinical guidelines encourage the adoption of statins among patients.

Government Support for Preventive Healthcare in Asia Pacific to Augment Demand

Asia Pacific statins market is predicted to hold a share of 15% in 2025. Urbanization and sedentary lifestyles are contributing to high rates of obesity, diabetes, and cholesterol levels in countries like China, India, and Indonesia. Statins are widely prescribed for individuals at risk of these conditions, boosting growth. Aging population in countries like Japan and South Korea is witnessing significant growth. For instance,

• According to the United Nations, by 2050, 28% of the Asia Pacific population will be aged 60 and older, increasing the prevalence of age-related cardiovascular diseases and statin prescriptions.

Government authorities across the region are investing in healthcare awareness campaigns while encouraging cholesterol screenings as part of preventive healthcare programs. For example,

• The Indian government launched the National Program for Prevention and Control of Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS) to promote statin use in high-risk patients.

Companies in the statins industry are investing in research and development activities to come up with improved formulations of existing statins or novel compounds that offer fewer side effects or enhanced efficacy. Several pharmaceutical companies are developing extended-release versions of statins to reduce side effects like muscle pain, which is a common concern among users.

Businesses are developing statin combinations with other cholesterol-lowering agents like ezetimibe or PCSK9 inhibitors, to improve patient outcomes. These combination drugs are being marketed as more effective in lowering cholesterol levels with fewer side effects. Pfizer has invested in the development of atorvastatin-based combinations, enhancing the efficacy of statin therapy and targeting broader segments of the market.

Recent Industry Developments

• In September 2024, a research study revealed that people over 70 should consider taking statins for better health outcomes for the age group. Borislava Mihaylova, an associate professor at Oxford Population Health and the lead author of the study said, “many people are suffering from preventable heart disease and stroke due to insufficient access to effect low-cost treatments.”
• In October 2024, the National Institute for Health and Excellence revealed that 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to reduce their cholesterol during 2023 to 2024, the largest number on record.
• In January 2024, a recent study by researchers at the Karolinska Institutet, published in Alzheimer Research and Therapy revealed an intriguing link between statins and Alzheimer’s progression. Patients diagnosed with Alzheimer’s dementia who received statin therapy showed slower cognitive decline compared to those who did not.